Condition: AML · Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · Sponsor: CERo Therapeutics Holdings, Inc.
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Not Yet Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Sarah Cannon Research Insitute | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06834282